Cardiome Pharma Corp. (CRME) Misses Q4 EPS by 1c

Cardiome Pharma Corp. (NASDAQ: CRME) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $1.37 million.

For earnings history and earnings-related data on Cardiome Pharma Corp. (CRME) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance